557 related articles for article (PubMed ID: 28669713)
21. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
Bellet M; Gray KP; Francis PA; Láng I; Ciruelos E; Lluch A; Climent MA; Catalán G; Avella A; Bohn U; González-Martin A; Ferrer R; Catalán R; Azaro A; Rajasekaran A; Morales J; Vázquez J; Fleming GF; Price KN; Regan MM
J Clin Oncol; 2016 May; 34(14):1584-93. PubMed ID: 26729437
[TBL] [Abstract][Full Text] [Related]
22. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
23. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
Tan SH; Wolff AC
Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
[TBL] [Abstract][Full Text] [Related]
24. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Michaud LB; Buzdar AU
Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant hormonal therapy for premenopausal women with breast cancer.
Emens LA; Davidson NE
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):486S-94S. PubMed ID: 12538505
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
Mathew A; Davidson NE
Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
[TBL] [Abstract][Full Text] [Related]
27. New insights into endocrine therapy for young women with breast cancer.
Di Lascio S; Pagani O
Womens Health (Lond); 2015 Jun; 11(3):343-54. PubMed ID: 26102472
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.
Regan MM; Pagani O; Fleming GF; Walley BA; Price KN; Rabaglio M; Maibach R; Ruepp B; Coates AS; Goldhirsch A; Colleoni M; Gelber RD; Francis PA; ;
Breast; 2013 Dec; 22(6):1094-100. PubMed ID: 24095609
[TBL] [Abstract][Full Text] [Related]
29. Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer.
Chlebowski RT; Pan K; Col NF
Breast Cancer Res Treat; 2017 Jan; 161(2):185-190. PubMed ID: 27785653
[TBL] [Abstract][Full Text] [Related]
30. Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression.
Yeo W; Ueno T; Lin CH; Liu Q; Lee KH; Leung R; Naito Y; Park YH; Im SA; Li H; Yap YS; Lu YS;
Breast Cancer Res Treat; 2019 Oct; 177(3):549-559. PubMed ID: 31270763
[TBL] [Abstract][Full Text] [Related]
31. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
[TBL] [Abstract][Full Text] [Related]
32. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
Mamounas EP; Jeong JH; Wickerham DL; Smith RE; Ganz PA; Land SR; Eisen A; Fehrenbacher L; Farrar WB; Atkins JN; Pajon ER; Vogel VG; Kroener JF; Hutchins LF; Robidoux A; Hoehn JL; Ingle JN; Geyer CE; Costantino JP; Wolmark N
J Clin Oncol; 2008 Apr; 26(12):1965-71. PubMed ID: 18332472
[TBL] [Abstract][Full Text] [Related]
33. Ovarian ablation for premenopausal breast cancer: A review of treatment considerations and the impact of premature menopause.
Nourmoussavi M; Pansegrau G; Popesku J; Hammond GL; Kwon JS; Carey MS
Cancer Treat Rev; 2017 Apr; 55():26-35. PubMed ID: 28288389
[TBL] [Abstract][Full Text] [Related]
34. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Gnant M; Mlineritsch B; Schippinger W; Luschin-Ebengreuth G; Pöstlberger S; Menzel C; Jakesz R; Seifert M; Hubalek M; Bjelic-Radisic V; Samonigg H; Tausch C; Eidtmann H; Steger G; Kwasny W; Dubsky P; Fridrik M; Fitzal F; Stierer M; Rücklinger E; Greil R; ; Marth C
N Engl J Med; 2009 Feb; 360(7):679-91. PubMed ID: 19213681
[TBL] [Abstract][Full Text] [Related]
35. Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL).
Lee J; Im SA; Kim GM; Jung KH; Kang SY; Park IH; Kim JH; Ahn HK; Park YH
Cancer Res Treat; 2021 Jul; 53(3):695-702. PubMed ID: 33332933
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.
Francis PA; Fleming GF; Láng I; Ciruelos EM; Bonnefoi HR; Bellet M; Bernardo A; Climent MA; Martino S; Bermejo B; Burstein HJ; Davidson NE; Geyer CE; Walley BA; Ingle JN; Coleman RE; Müller B; Le Du F; Loibl S; Winer EP; Ruepp B; Loi S; Colleoni M; Coates AS; Gelber RD; Goldhirsch A; Regan MM;
J Clin Oncol; 2023 Mar; 41(7):1370-1375. PubMed ID: 36493334
[No Abstract] [Full Text] [Related]
37. Tamoxifen for early breast cancer.
Early Breast Cancer Trialists' Collaborative Group
Cochrane Database Syst Rev; 2001; (1):CD000486. PubMed ID: 11279694
[TBL] [Abstract][Full Text] [Related]
38. Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.
Sverrisdottir A; Johansson H; Johansson U; Bergh J; Rotstein S; Rutqvist L; Fornander T
Breast Cancer Res Treat; 2011 Aug; 128(3):755-63. PubMed ID: 21625929
[TBL] [Abstract][Full Text] [Related]
39. [New options in adjuvant endocrine therapy in breast cancer].
Saltel-Fulero A; Donnadieu A; Leman-Detours S; Cottu P
Bull Cancer; 2016 Jan; 103(1):104-12. PubMed ID: 26675809
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.
Derks MGM; Blok EJ; Seynaeve C; Nortier JWR; Kranenbarg EM; Liefers GJ; Putter H; Kroep JR; Rea D; Hasenburg A; Markopoulos C; Paridaens R; Smeets JBE; Dirix LY; van de Velde CJH
Lancet Oncol; 2017 Sep; 18(9):1211-1220. PubMed ID: 28732650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
